34  3.17 (10.28%)		09-29 16:00
Open: 32.4 High: 36.08 Volume: 96,905		Pre. Close: 30.83 Low: 30.94 Market Cap: 159(M)

Short term
Mid term
Targets	6-month :	43.52	1-year :	50.83
Resists	First :	37.26	Second :	43.52
Pivot price	31.98
Supports	First :	26.43	Second :	19.73
MAs	MA(5) :	33.06	MA(20) :	31.43
	MA(100) :	25.59	MA(250) :	0
MACD	MACD :	1.5	Signal :	1.5
%K %D	K(14,3) :	69.1	D(3) :	74.8
RSI	RSI(14): 55.2
52-week	High :	59.36	Low :	7.18

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ KRSA ] has closed below upper band by 33.8%. Bollinger Bands are 143.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	36.13 - 36.33	36.33 - 36.52
Low:	30.47 - 30.7	30.7 - 30.92
Close:	33.63 - 34	34 - 34.34

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Tue, 29 Sep 2026
KRSA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Mon, 28 Sep 2026
KRSA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Sun, 27 Sep 2026
Korsana Biosciences (KRSA) Stock Analysis Report | Financials & Insights - Benzinga

Sun, 27 Sep 2026
Korsana Biosciences (KRSA) Stock Price, News & Analysis - Stock Titan

Thu, 24 Sep 2026
Korsana Biosciences, Inc. (KRSA) recent insider transactions - Yahoo Finance UK

Wed, 23 Sep 2026
Korsana Biosciences, Inc. (KRSA) stock major holders - Yahoo Finance UK

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.